

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/758,717 01/16/2004		01/16/2004	James R. Dasch	1733.1068-008	6559
21005	7590	12/05/2005		EXAMINER	
	•	OK, SMITH & RI	RUSSEL, J	RUSSEL, JEFFREY E	
530 VIRGIN P.O. BOX 9)	ART UNIT	PAPER NUMBER	
CONCORD		742-9133	1654		

DATE MAILED: 12/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
Office Action Summary		10/758,717	DASCH ET AL.	
		Examiner	Art Unit	
		Jeffrey E. Russel	1654	
	The MAILING DATE of this communication app	•	orrespondence address	
Period fo	r Reply			
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE IS IN A COMMENT OF THE MAILING DATE IS A C	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. O (35 U.S.C. § 133).	
Status				
2a)⊠	Responsive to communication(s) filed on <u>03 Octoors</u> This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	secution as to the merits is	
Dispositi	on of Claims			
5)⊠ 6)⊠ 7)□ 8)□	Claim(s) 1,3-5 and 8 is/are pending in the application of the above claim(s) is/are withdraw Claim(s) 1 and 3-5 is/are allowed. Claim(s) 8 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.		
Applicati	on Papers			
10)⊠	The specification is objected to by the Examine The drawing(s) filed on 16 January 2004 is/are: Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Example 1.	a)⊠ accepted or b)□ objected drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority u	nder 35 U.S.C. § 119			
a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau ee the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage	
	e of References Cited (PTO-892)	4) 🔲 Interview Summary		
3) 🔯 Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date 20051125.	Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te atent Application (PTO-152)	

Art Unit: 1654

- 1. The terminal disclaimer filed October 3, 2005 has been approved.
- The text of those sections of Title 35, U.S. Code not included in this action can be found 2. in a prior Office action.
- Claim 8 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply 3. with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no original disclosure supporting the recitation in claim 8 that the concentration of the bisphosphonate is from about 0.5% (w/w) to about 20% (w/w) of the total weight of the composition. While this numerical range is used to describe the concentration of biologically active agents in the composition (see page 9, line 18 - page 10, line 3), the bisphosphonate is a component separate and distinct from the biologically active agents (see, e.g., page 5, lines 25-28). Note that while this claim limitation occurs in a preliminary amendment to the application, the preliminary amendment does not form part of the original disclosure of the application because the application was filed with a copy of the declaration filed in the parent application. See MPEP 714.01(e)(II).
- 4. Applicant's arguments filed October 3, 2005 have been fully considered but they are not persuasive.

The rejection of claim 8 under 35 U.S.C. 112, first paragraph, is maintained. The rejection acknowledges the disclosure at page 9, line 18 - page 10, line 3, of the specification of the concentration range "from about 0.5% to about 20% (w/w) of the total weight of the

Application/Control Number: 10/758,717 Page 3

Art Unit: 1654

composition". However, this section of the specification is limited to a discussion of biologically active agents which are present in the sustained release compositions. Applicants' specification at page 5, lines 25-28, distinguishes between biologically active agents and bisphosphonates. The claimed bisphosphonates are not biologically active agents as the terms are defined and used in Applicants' specification. Accordingly, the description of the concentration of biologically active agents does not constitute a description of the concentration of the bisphosphonates. The two single bisphosphonate concentrations disclosed at page 22, lines 25-27, of the specification are not sufficient in and of themselves to support the broader claimed range.

- 5. Claims 1 and 3-5 are allowed.
- 6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/758,717 Page 4

Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (571) 272-0969. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Bruce Campell can be reached at (571) 272-0974. The fax number for formal communications to be entered into the record is (571) 273-8300; for informal communications such as proposed amendments, the fax number (571) 273-0969 can be used. The telephone number for the Technology Center 1600 receptionist is (571) 272-1600.

Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

JRussel

December 2, 2005